Jubilant Ingrevia Q1 FY27 Earnings Call Transcript Released
Jubilant Ingrevia reported Q1 FY27 revenue of ₹1,300 crore, up 25% YoY, and EBITDA of ₹209 crore, up 36% YoY. PAT was ₹106 crore, a 41% YoY increase. The company maintains its FY27 EBITDA guidance of ₹750-800 crore and expects sequential growth.
The announcement details strong quarterly financial performance and provides insights into the company's strategic progress and future growth drivers, which are material for investors.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with positive commentary on future outlook and business momentum.
Jubilant Ingrevia Limited has released the transcript of its Investors' Conference Call for the quarter ended June 30, 2026, which was held on July 23, 2026. The call featured management including Chairman Mr. Shyam S Bhartia, CEO and Managing Director Mr. Deepak Jain, and CFO Mr. Varun Gupta.
During the call, the company reported a strong start to FY27, with revenue growing 25% year-on-year to ₹1,300 crore and EBITDA increasing by 36% year-on-year to ₹209 crore. PAT stood at ₹106 crore, up 41% year-on-year. The Specialty Chemicals business reported revenue of ₹533 crore, up 11% year-on-year, with EBITDA at ₹139 crore. The Nutrition & Health segment saw revenue grow to ₹243 crore, up 36% year-on-year, with EBITDA at ₹36 crore. The Chemical Intermediates business rebounded with revenue of ₹524 crore, up 38% year-on-year, and EBITDA at ₹57 crore.
Management expressed confidence in continued growth momentum, expecting sequential improvement in revenue and EBITDA. The company is on track to commission its new multipurpose plant by the end of the calendar year, strengthening its CDMO and Fine Chemicals roadmap. The CDMO and Fine Chemicals pipeline shows over 100 molecules with INR3,500 crore+ peak revenue potential, with 25+ confirmed molecules. The company is also building a dedicated R&D and clean room facility for semiconductors and electronics.
Discussions also covered the contribution of a large CDMO contract, volume and pricing trends across segments, the company's full-year EBITDA guidance of ₹750 crore to ₹800 crore, and the impact of market dynamics on pricing and costs. The integration of Remidex Pharma was successfully completed, and the company hosted an Investor and Analyst Day at its Bharuch facility.
What to do with a filing like this
Jubilant Ingrevia Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Ingrevia Limited. Read the original for the full detail.